• Revenue up 8% to $4.353M
• Expenses down 3% to $5.040M
• EBITDA improved 55% to ($480K)

Global Health Limited (ASX:GLH) reported its financial results for the half-year ended 31 December 2024. The Group's revenue increased by 8% to $4.353M compared to the previous corresponding period, despite challenging external conditions. This was achieved through sales to new customers and value-add sales to existing customers. Total expenses were reduced by 3% to $5.040M, leading to a 55% improvement in EBITDA to ($480K). Research and development expenses were reduced by 24% to $1.110M, representing 22% of total expenses compared to 28% in the previous period. The company's operating and investing cashflow improved by 56% to ($541K), while the group's overall cashflow improved by 70% to ($254K). The company raised $350K through the issue of convertible notes and repaid $136K of debt. Global Health is well-positioned to generate better results in the second half of 2025, with a growing pipeline of new clients and upgrades to existing clients. The company is focused on improving operating efficiencies and productivity of its private hospital clients, while also benefiting from growth in the mental health and community healthcare sectors. Global Health is also working to incorporate AI technology into its platforms to improve productivity and efficiency in the healthcare industry.

Global Health expects to generate better results in the 2HY 2025, with a growing pipeline of new clients and upgrades to existing clients.

Global Health is well-placed to generate better results in the 2HY 2025, with a growing pipeline of new clients and upgrades to existing clients. The company is focused on improving operating efficiencies and productivity of its private hospital clients, while also benefiting from growth in the mental health and community healthcare sectors. Global Health is also working to incorporate AI technology into its platforms to improve productivity and efficiency in the healthcare industry.